Skip to main content
    R

    Rocket Pharmaceuticals Inc (RCKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.11
    -0.05 (-2.31%)

    Market Cap: $241.19M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Rocket Pharmaceuticals Inc (RCKT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Rocket Pharmaceuticals (RCKT) has a market cap of $241.19M and an enterprise value of $176.14M. Revenue fell 100.00% over the last 12 months from the 12 months before. It holds $65.04M more cash than debt, 26.97% of its market cap.

    Total Valuation

    Enterprise value is 26.97% below the market cap, as cash exceeds debt.

    Market Cap$241.19M
    Enterprise Value$176.14M
    Latest price (Nov 17, 2026)$2.11

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.71% in the quarter ended Sep 30, 2026 and grew 9.86% a year over 2 years.

    Shares Outstanding113.65M
    Shares Change (YoY)+1.86%
    Shares Change (QoQ)+0.71%
    Share Count Growth (2Y CAGR)+9.86%

    Valuation Ratios

    Forward P/S261.9x
    P/B Ratio0.7x
    P/TBV Ratio0.9x

    Price Statistics

    The stock is down 30.82% over 52 weeks and trades 20.38% below its 50-day average.

    Beta (1Y)1.79
    52-Week Change-30.82%
    1-Month Change-5.80%
    3-Month Change-42.19%
    6-Month Change-27.74%
    5-Year Change-91.79%
    10-Year Change-91.29%
    Total Return (1Y)-30.82%
    Total Return (3Y CAGR)-54.18%
    Total Return (5Y CAGR)-39.99%
    Return vs SPY (1Y)-39.79%
    Max Drawdown (1Y)-60.19%
    Max Drawdown (3Y)-93.39%
    Sharpe Ratio (1Y)-0.48
    Correlation with SPY (1Y)0.36
    50-Day Average$2.65
    200-Day Average$3.38
    52-Week Range$2.15 to $5.45
    RSI (14 Days)35.6
    Average Volume (20 Days)1.65M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.26x current liabilities, and total debt is 0.09x shareholder equity.

    Current Ratio7.26x
    Quick Ratio7.25x
    Debt / Equity0.09x
    Interest Coverage-5.41x

    Returns and Efficiency

    Return on invested capital is -2.26% over the last 12 months, against a 5-year average of -66.04%.

    Return on Equity (ROE)-4.94%
    Return on Assets (ROA)-3.85%
    Return on Invested Capital (ROIC)-2.26%
    ROE (5Y Average)-53.74%
    ROA (5Y Average)-46.83%
    ROIC (5Y Average)-66.04%

    Scores

    RCKT has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Operating Income-$190.36M
    Pretax Income-$9.91M
    Net Income-$16.15M
    EBITDA-$2.83M
    Reported EPS (TTM)-$1.38

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 77.88% of the $419.50M in total assets.

    Cash and Equivalents$95.47M
    Total Debt$30.43M
    Net Cash$65.04M
    Net Cash Per Share$0.57
    Working Capital$239.73M
    Shareholder Equity$326.72M
    Book Value Per Share$2.87
    Tangible Book Value$262.42M
    Tangible Book Per Share$2.31
    Total Assets$419.50M
    Total Liabilities$92.78M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $332.00K of capital spending, operating cash flow left -$159.23M of free cash flow.

    Operating Cash Flow-$158.90M
    Capital Expenditures$332.00K
    Free Cash Flow-$159.23M
    FCF Per Share-$1.45
    Depreciation and Amortization$8.51M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-34.77%
    Tangible Book Per Share Growth (2Y CAGR)-38.69%

    Revenue and profit by year

    Dividends and Yields

    RCKT does not pay a dividend. Its free cash flow yield is -66.40%.

    FCF Yield-66.40%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-4 reverse split on Jan 5, 2018.

    Last Split DateJan 5, 2018
    Split TypeReverse split
    Split Ratio1:4

    Peer Position

    Against 4 similar companies, RCKT has the highest ROIC.

    ROIC-2.26% vs -76.25% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -75.60% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RCKT

    What is RCKT's market cap?

    Rocket Pharmaceuticals has a market cap of $241.19M. Its enterprise value, which adds debt and subtracts cash, is $176.14M.

    How many shares of RCKT are outstanding?

    Rocket Pharmaceuticals has 113.65M shares outstanding. The count is up 1.86% from a year earlier.

    Does RCKT pay a dividend?

    No. Rocket Pharmaceuticals does not pay a dividend.

    How much debt does RCKT have?

    Rocket Pharmaceuticals has $30.43M of total debt and $95.47M of cash and equivalents, a net cash position of $65.04M.